Paraneoplastic sensory neuronopathy …

Neuro-Oncology

Updated 04.23.2024
Released 09.02.1994
Expires For CME 04.23.2027

Paraneoplastic sensory neuronopathy

Authors: Arjun Seth MD, Glenn R Harris MD

See Contributor Disclosures

Editor: Rimas V Lukas MD

Paraneoplastic sensory neuronopathy

In This Article

Quick Link

Introduction

Overview

Paraneoplastic sensory neuronopathy is a rare but potentially devastating complication of systemic neoplasms and is most commonly associated with small cell lung carcinoma (75). In some patients, the sensory neuronopathy is part of a multifocal encephalomyeloneuritis. The disorder is believed to arise from an autoimmune response directed against onconeural antigen(s) shared by tumor cells and primary sensory neurons in the dorsal root ganglia. Early identification of this syndrome and treatment of the underlying tumor can improve the likelihood of neurologic recovery, although most patients are severely and permanently disabled. The authors summarize the clinical presentation, autoimmune features, and treatment options for patients with paraneoplastic sensory neuronopathy.

Key points

	• Paraneoplastic sensory neuronopathy (dorsal root ganglionitis) is most often associated with small cell lung carcinoma, breast and gynecologic cancers, and lymphoma (146).
	• Paraneoplastic sensory neuronopathy may occur as part of a multifocal encephalomyeloneuritis or may be an isolated clinical syndrome.
	• Paraneoplastic sensory neuronopathy is often disabling due to painful dysesthesias, profound loss of proprioception, and sensory gait ataxia.
	• Most patients with paraneoplastic sensory neuronopathy and small cell lung cancer do not show significant neurologic improvement despite successful tumor treatment or immunosuppressive therapy, though there are some notable exceptions.

Historical note and terminology

In 1948 Denny-Brown reported two patients with sensory neuropathy in whom autopsy revealed severe neuronal loss in the dorsal root ganglia and a previously undiagnosed bronchial carcinoma (50).

Clinical manifestations

Presentation and course

In the majority of patients with paraneoplastic sensory neuronopathy (up to 86%), the neurologic symptoms are the presenting feature of the associated neoplasm, preceding discovery of the tumor by intervals ranging from several months up to 2 years or more (92; 31; 100; 73; 154; 180). The most prominent early symptoms are acute to subacute numbness and paresthesias, often patchy or asymmetric at onset, often involving the arms but eventually involving all limbs (50; 36; 92; 31; 133; 105; 94; 70; 181). However, the clinical course has been reported to be more insidious in about 10% of cases (118). Burning dysesthesias and severe aching or lancinating pain occur in a majority of patients and may be the most distressing feature of the disease (83). Sensory involvement of the face, trunk, or abdomen may help point toward the diagnosis (98). Examination may reveal severe sensory ataxia and predominant impairment of vibration sense and proprioception, although all sensory modalities are generally involved. Pseudoathetosis is common. Muscle stretch reflexes are diffusely hypoactive or absent. True weakness is rare and may be seen due to additional involvement of motor nerve roots, but patients with severely impaired proprioception may also have difficulty in sustaining effort during the motor examination (75). Most patients cannot walk unassisted due to pain and profound loss of proprioception. A minority of patients have prominent pain and mechanical hyperalgesia with at least partial preservation of large fiber sensibility and muscle stretch reflexes (111; 133). Dysautonomia is also common, with gastrointestinal dysmotility being a frequent manifestation (180).

In 2004, the Paraneoplastic Euronetwork consortium for paraneoplastic neurologic disorders suggested diagnostic criteria for paraneoplastic sensory neuronopathy, stating that a classical sensory neuronopathy should have the following characteristics: (1) subacute onset with a Rankin score of at least 3 before 12 weeks of evolution; (2) onset of numbness and often pain; (3) asymmetry of symptoms at onset; (4) arm involvement; (5) proprioceptive loss in areas affected; and (6) electrodiagnostic studies that demonstrate pronounced sensory fiber involvement and at least one absent sensory nerve action potential (72). In the updated 2021 diagnostic criteria for paraneoplastic neurologic syndromes, the clinical presentation of sensory neuronopathy is no longer referred to as a “classical paraneoplastic syndrome,” but it is now defined as a “high-risk phenotype” that frequently has a paraneoplastic etiology (75).

Many patients with paraneoplastic sensory neuronopathy have additional signs and symptoms that reflect a multifocal encephalomyeloneuritis. These include varied combinations of altered sensorium, confusion, memory loss, personality change, ocular dysmotility, dysarthria, dysphagia, cerebellar ataxia, corticospinal tract findings, asymmetric lower motor neuron weakness, intestinal pseudo-obstruction, or autonomic system degeneration (31; 40; 116; 100; 73; 154; 133). Conversely, patients with predominant limbic or cerebellar manifestations of paraneoplastic encephalomyeloneuritis often also have a component of sensory neuronopathy. Some patients with sensory neuronopathy develop concomitant Lambert-Eaton myasthenic syndrome, a component of motor neuropathy, or peripheral nerve microvasculitis presenting as mononeuritis multiplex (178; 58; 73).

The great majority of patients with paraneoplastic sensory neuronopathy or encephalomyeloneuritis deteriorate over weeks to months and then plateau at a level of severe disability with little to no improvement despite therapy (181). Less commonly, patients have stepwise deterioration (141) or exhibit a relentlessly progressive course leading to coma and death. Exceptional patients may have few, if any, overt central nervous system manifestations and a relatively indolent sensory neuronopathy that does not progress to neurologic disability even over several years (68).

Prognosis and complications

The course of paraneoplastic sensory neuronopathy in patients with small cell lung carcinoma is fairly stereotyped. Most patients deteriorate over several weeks or months and then stabilize at a level of severe neurologic disability (40; 73; 154; 03). Subsequent stepwise or gradual neurologic deterioration is less common and tends to occur in patients with less than complete response of the associated small cell lung cancer to treatment (100). Sudden, unexpected death is not rare and is presumed to be caused by acute dysautonomia. Conversely, a few patients have minimal central nervous system manifestations and a sensory neuronopathy that takes a relatively indolent course independent of any treatment (68). Paraneoplastic sensory neuronopathy or encephalomyelitis associated with anti-Hu (ANNA-1) antibodies may rarely spontaneously improve without any specific treatment (23; 144). The presence of paraneoplastic antibodies may be suggestive of an effective antitumor immune response, evident by the longer survival in patients with some autoantibodies in small cell lung carcinoma patients (66). One study that evaluated prognostic factors for paraneoplastic neurologic syndromes (including neuropathy) associated with small cell cancer found that autoantibody positivity or type of neurologic syndrome did not correlate with overall survival (180). The only exception was for paraneoplastic myelopathy, which was associated with reduced survival rates.

Clinical vignette

A 52-year-old right-handed woman without significant medical history other than cigarette smoking was found to have a possible right perihilar mass by chest x-ray done as part of a routine checkup. Bronchoscopy and transbronchial needle biopsy showed no definite tumor. Repeat chest x-ray 3 months later was unchanged, but she reported anorexia, constipation, and a 20 lb weight loss. Seven months after the initial chest x-ray, she developed numbness and painful dysesthesias extending from the elbows into all 10 fingers, much worse on the right side, with clumsiness of the right hand. She had similar numbness and dysesthesias from the left posterior thigh into the sole, with occasional "shooting" pains. CSF contained 12 white blood cell/mm³ and protein 88 mg/dL. The patient was prescribed trazodone for symptoms of depression, but after 1 week she became confused and had three generalized tonic-clonic seizures. A brain MR scan showed several small areas of abnormal signal in the hemispheric white matter. EEG showed left temporal lobe sharp waves. Repeat lumbar puncture showed 20 mononuclear white blood cells, protein 53 mg/dL, IgG index 2.5 (normal less than 0.7), and two oligoclonal bands. Phenytoin was begun and trazodone discontinued.

Over the next 3 weeks, the patient developed a weak voice, nasal regurgitation, a feeling of "swelling" in her throat, intermittent diplopia and vertigo, "wobbly" gait, and memory difficulty. On referral to another neurologist, she had impaired short-term memory, diminished attention, and poor insight into her condition. Cranial exam showed vertical nystagmus on upward gaze, mild dysarthria, and myoclonic twitching of the larynx, lower lip, and left cervical strap muscles. Strength was normal except for 4+/5 bilateral proximal arm weakness and difficulty in sustaining effort with the right arm and hand. Muscle stretch reflexes were exaggerated in the left arm and barely able to be elicited in the other limbs. Plantar response was flexor bilaterally. Proprioception and vibratory sense were diminished in the right arm, and additionally there was stocking-glove impairment of light touch and pinprick. There was moderate ataxia and dysmetria of the right arm. Romberg test was positive, and gait was moderately ataxic.

Nerve conduction studies showed absent sensory nerve action potentials in both sural nerves and the right median nerve and reduced sensory amplitudes in several other nerves. Chest CT scan demonstrated a right hilar and subcarinal mass. Biopsy of a newly palpable supraclavicular lymph node demonstrated small cell lung carcinoma. Staging workup revealed no other evident tumor. Serum and CSF contained high-titer anti-Hu (ANNA-1) antibodies.

The patient was given clonazepam, prednisone 60 mg per day, and monthly chemotherapy (cyclophosphamide + doxorubicin + vincristine). After three cycles of chemotherapy and 2 months of prednisone, tumor response was significant, but she reported worsening dysarthria, dysphagia, numbness and dysesthesias of all four limbs, and decreased gait stability. Repeat brain MR scan was unchanged. EMG testing showed no evidence for Lambert-Eaton myasthenic syndrome. Prednisone was tapered, and she received a course of six plasma exchanges. After 2 weeks she reported slight improvement in swallowing and gait stability; neurologic exam was unchanged. One month later she had another seizure and developed worsening diplopia, dysarthria, dysesthesias, and sensory gait ataxia (despite complete tumor remission after six cycles of chemotherapy). Prednisone was increased back to 60 mg per day, without clinical benefit. She died suddenly at home 2 months later.

Biological basis

Etiology and pathogenesis

The clinical features, electrophysiologic abnormalities, and neuropathology of paraneoplastic sensory neuronopathy indicate that the cell body of primary sensory neurons is the primary site of injury. The leading theory at present is that an autoimmune response initially directed against tumor cell antigens subsequently "spills over" to attack dorsal root ganglion neurons (and other neurons) (53; 62). The inflammatory infiltrates or antineuronal antibodies present in some patients indirectly support an autoimmune etiology, but the actual pathophysiologic mechanisms remain unknown.

Pathology. The neuropathologic hallmark of paraneoplastic sensory neuronopathy is severe dropout of primary sensory neurons in the dorsal root ganglia and gasserian ganglia (50; 36; 92; 93). The neuronal loss is diffuse but patchy and usually asymmetric, reflecting patients' clinical presentation. Large-diameter neurons are probably lost preferentially (131; 93). Remaining neurons occasionally show nonspecific degenerative changes. Nodules of Nageotte are often present. There is a highly variable degree of infiltration by T and B lymphocytes, plasma cells, and macrophages, often in a perivascular distribution (134; 175). Severe depletion of myelinated fibers is present in dorsal columns, posterior nerve roots, and peripheral sensory nerves, believed to be secondary to the loss of dorsal root ganglia neurons.

There are well-documented cases of sensory neuronopathy associated with small cell lung carcinoma in which the pathological abnormalities are restricted to the findings listed above (50; 36; 104). Some of the patients with sensory neuronopathy, however, have multifocal encephalomyeloneuritis, with patchy neuronal loss and variable inflammatory infiltrates in any or all areas of the nervous system including the cerebral hemispheres, limbic system, brainstem, cerebellum, gray matter of the spinal cord, dorsal root ganglia, and autonomic ganglia (36; 88; 73). Neuronal loss is accompanied by a variable degree of perivascular and leptomeningeal infiltration of mononuclear cells, including T and B lymphocytes and plasma cells (17). There is only a rough correlation between individual patients' clinical manifestations and the severity of neuronal loss and inflammatory changes in different sites seen at autopsy (38). Microvasculitis of peripheral nerves may rarely be superimposed on the encephalomyelitis (99; 178; 58).

Immunology. The theory that paraneoplastic sensory neuronopathy/encephalomyelitis is an autoimmune disorder is supported by the "inflammatory" histopathology and by the presence in some patients of circulating antineuronal autoantibodies. The most prevalent of these autoantibodies are polyclonal IgG anti-Hu antibodies (also called type 1 antineuronal nuclear antibodies [ANNA-1]). Anti-Hu antibodies are present in up to 2% of cancer patients and were initially found in patients with small cell lung carcinoma and paraneoplastic sensory neuronopathy (69; 114). It has since been described in patients with various clinical manifestations of paraneoplastic encephalomyeloneuritis (40; 116; 100). Around 85% of patients with anti-Hu antibodies and paraneoplastic encephalomyeloneuritis have small cell lung carcinoma, with reports of patients with other tumors, including neuroblastoma, nonsmall cell lung carcinoma, or carcinoma of the breast, ovary, or prostate (14; 73; 147). In one series, sensory neuronopathy was the most common presentation in patients with anti-Hu antibodies, occurring in about 54% of cases (142).

Immunohistochemical studies utilizing anti-Hu antibodies stain the nuclei and, to a lesser degree, the cytoplasm of all neurons in the human brain, spinal cord, dorsal root ganglia, and myenteric plexus (69; 01). In immunoblots of human neuronal extracts, anti-Hu antibodies react with a group of closely spaced 35- to 40-kd proteins. Intrathecal synthesis of anti-Hu antibodies (out of proportion to the serum titer) is common (145) and is probably more prevalent among patients with clinically overt encephalomyelitis plus sensory neuronopathy than among patients with relatively "pure" sensory neuronopathy (169).

Anti-Hu antibodies react with a group of neuronal protein autoantigens, which are closely related structurally and antigenically but are encoded by different genes. The cloned protein autoantigens include HuD, HuB, HuC, and HuR (158; 103; 151). These proteins bind to AU-rich elements in the 3' untranslated region of mRNAs and regulate the stability of mRNA transcripts. The proteins thereby play a key role in the development, maturation, and maintenance of neurons (89; 20; 21). Multiple isoforms of the Hu proteins differ in their neuronal distribution and antigenicity (153).

Expression of one or more Hu autoantigens is common but is not universal among small cell lung carcinomas, including tumors from patients with paraneoplastic sensory neuronopathy or encephalomyelitis and anti-Hu antibodies as well as tumors from neurologically unaffected patients (39). There is marked heterogeneity in the level of expression of mRNA for individual Hu proteins among individual tumors (117; 52). No definite genetic mutations or antigenic differences have been identified between Hu autoantigens expressed by tumors from paraneoplastic sensory neuronopathy or encephalomyelitis patients and the proteins from neurologically unaffected small cell carcinoma patients (153).

At least a portion of the polyclonal anti-Hu antibody response in paraneoplastic sensory neuronopathy or encephalomyelitis is probably directed against one or more epitopes shared by the Hu autoantigens (55). These shared epitopes most likely reside in the portions of highest sequence homology among the autoantigens, namely, in the "RNA recognition motifs" that bind RNA. Differences in the fine specificity of the anti-Hu autoimmune response among different individuals may in part explain the clinical heterogeneity of patients with paraneoplastic sensory neuronopathy or encephalomyelitis.

To date, no fully successful experimental model exists for paraneoplastic sensory neuronopathy or encephalomyelitis. Passive transfer of human anti-Hu antibodies into mice fails to produce any histopathologic changes in the cerebellum, spinal cord, or dorsal root ganglia. In vitro incubation of patients' anti-Hu sera with human tumor cell lines or neuronal cultures has produced apoptosis or cytotoxicity in some laboratories but not in others (77; 90; 160). Animals actively immunized with recombinant Hu antigens (156; 155) or with HuD DNA vaccination (27) produce anti-Hu antibodies, but they do not develop the clinical or pathologic features of sensory neuronopathy or encephalomyelitis.

Currently, it is believed that cellular immune effectors, and not anti-Hu antibodies, directly cause neuronal injury in paraneoplastic sensory neuronopathy or encephalomyelitis. The growing evidence for T lymphocyte-mediated neuronal injury includes: increased numbers of CD4+ lymphocytes, CD8+ T lymphocytes, regulatory T cells, and dendritic cells in the CSF of patients (45; 47); the presence of CD8+ T cells expressing cytotoxic proteins and clustered around neurons in brain and dorsal root ganglia (17; 19); stimulation of lymphocyte proliferation by recombinant HuD protein in vitro (16; 84); clonal expansion of certain T cell receptors in patients with paraneoplastic sensory neuronopathy or encephalomyelitis (174); and oligoclonal T cells in the blood and dorsal root ganglia of patients with anti-Hu antibodies (140). Circulating HuD-specific cytotoxic CD8+ T lymphocytes in affected patients were found in some studies (162; 161; 139; 149) but not in others (44; 46).

In a disproportionately high percentage of patients with paraneoplastic sensory neuronopathy or encephalomyelitis and anti-Hu antibodies, the associated small cell lung carcinoma is limited to the lung and mediastinum as compared with neurologically unaffected small cell cancer patients (71). Patients with anti-Hu antibody-associated sensory neuronopathy or encephalomyelitis appear to have a longer survival than patients with small cell lung cancer but no paraneoplastic syndrome (100). This is circumstantial evidence supporting an antitumor immune response, but an alternative explanation is that the occurrence of neurologic symptoms leads to early tumor diagnosis and treatment. There are reports of spontaneous regression of small cell cancer accompanied by or shortly preceding the onset of anti-Hu antibody-positive paraneoplastic sensory neuronopathy or encephalomyelitis (42; 63); whether the anti-Hu immune response is directly involved in this is unknown.

Some patients with paraneoplastic sensory neuronopathy or sensorimotor polyneuropathy, most of who have small cell lung carcinoma, have autoantibodies distinct from anti-Hu antibodies (Table 1).

Next to anti-Hu antibodies, anti-CV2/CRMP5 antibodies are the most common. The collapsin-response mediator proteins (CRMP) are found in the adult central and peripheral neurons in addition to small cell lung carcinomas (179). Unlike anti-Hu antibodies, anti-CV2/CRMP5 cross react with antigens on peripheral nerves and may demonstrate demyelination and axonal degradation with perivascular inflammation on biopsy (06; 57). The perivascular inflammation can encroach on the smallest nerve venules and capillaries, a hallmark of nonsystemic nerve vasculitis. Clinically, these patients present with a very painful axonal polyradiculoneuropathy, which is usually asymmetric (57). Patients may have concomitant cerebellar ataxia, myelopathy, or optic neuritis/retinitis. Electrodiagnostic studies show axonal or mixed axonal and demyelinating pattern and may mimic chronic inflammatory demyelinating polyneuropathy (CIDP). Small cell lung cancer was found in 75% of patients, and 15% had a thymoma. Symptoms typically preceded detection of underlying malignancy by months to years. Overall survival in these patients is, on average, better than those with anti-Hu (57).

In one series, contactin-1 IgG seropositivity was most commonly manifested as a sensory predominant demyelinating neuropathy (56). Sensory symptoms such as numbness, paresthesias, and sensory ataxia typically preceded any signs of weakness with a third of cases involving cranial nerves. Nerve conduction studies demonstrated prolonged distal latencies and slowed conduction velocities. Somatosensory evoked potentials in some cases were prolonged, suggesting proximal localization to the sensory nerve roots or dorsal root ganglia. Associated malignancies included thymomas, breast cancer, and plasmacytoma (56).

There are also case reports of sensory neuronopathy associated with inositol 1,4,5-triphosphate receptor type 1 (ITPR1) (97), anti-SOX1/AGNA (166; 61), anti-Yo (159), anti-Ma2 (10), antiampiphysin (34), ANNA-3 (32), anti-NIF (12), and anti-Trk paraneoplastic antibodies (126). There is also one described instance of a patient with anti-GFAP meningitis who also developed a sensory neuronopathy (76; 163). Patients may have more than one type of antineuronal antibody (06; 136). Up to 16% of patients with small cell lung cancer and paraneoplastic sensory neuronopathy or encephalomyelitis have no detectable antineuronal antibodies (121). The clinical features of paraneoplastic sensory neuronopathy or encephalomyelitis in these “anti-Hu antibody-negative” patients do not differ from the spectrum of abnormalities in patients with anti-Hu antibodies.

Table 1. Antineuronal Antibodies in Paraneoplastic Sensory Neuronopathy and Sensorimotor Polyneuropathy

Antineuronal antibody	Associated tumors	Antibody reactivity
Anti-Hu (ANNA-1)	Small cell lung carcinoma, others	Pan-neuronal nuclei > cytoplasm; 35-40 kD RNA-binding proteins
Anti-CV2 (CRMP-5) (07; 179)	Small cell lung carcinoma, others	Cytoplasm of neurons and oligodendrocytes; 66 kD CV2 protein
Anti-amphiphysin (52)	Small cell lung carcinoma, breast carcinoma	Neuropil; synaptic vesicle-associated amphiphysin
ANNA-3 (32)	Small cell lung carcinoma	Purkinje cell and dentate neuronal nuclei; 170 kD protein
Anti-Ma	Lung, other carcinomas	Pan-neuronal nuclei and nucleoli; 37 kD Ma1 and 40 kD Ma2 proteins
Anti-Yo (PCA-1) (120; 29)	Ovarian carcinoma, breast cancer	Neuronal cytoplasm

Differential diagnosis

The differential diagnosis of paraneoplastic sensory neuronopathy is fairly extensive and includes a variety of disorders that selectively affect sensory neurons or sensory nerve fibers (108; 25; 04).

There are several well-documented patients with multifocal encephalomyeloneuritis, many with prominent sensory neuronopathy, whose clinical presentations and pathologic findings are indistinguishable from those of the paraneoplastic disorder, but in whom no tumor is ever discovered, even at autopsy (91; 41).

Subacute sensory neuronopathy can occur in patients with Sjögren syndrome (79; 124); in many of these patients, the neurologic condition precedes recognition of Sjögren syndrome. Predominant loss of proprioception and vibratory sense (including the face and trunk), pseudoathetosis, areflexia, and sensory gait ataxia closely resemble the findings in paraneoplastic sensory neuronopathy. Biopsy of dorsal root ganglia has demonstrated neuronal loss and lymphocytic infiltration.

Sensory neuronopathy can occur in patients with gluten sensitivity. A few autopsied cases showed inflammation of the dorsal root ganglia and degeneration of the posterior columns of the spinal cord (86).

Pyridoxine toxicity is a well-documented cause of symmetric, pure sensory neuropathy (152). Most patients subacutely develop distal numbness and paresthesias and disproportionate impairment of vibratory sense and proprioception. Lhermitte symptom is often present, consistent with combined central and peripheral degeneration of large-diameter axons (02). Partial recovery occurs after the pyridoxine is stopped.

There are numerous reports of idiopathic sensory neuronopathy, sensory neuropathy, or ataxic neuropathy with the tempo of the disease ranging from acute and fulminant to chronic and slowly progressive (37; 177; 95). These patients share a clinical profile of numbness, paresthesias, dysesthesias (often asymmetric and involving the face and trunk), disproportionate impairment of proprioception and kinesthetic sensation, areflexia, preserved strength, and ataxic gait, all leading to severe disability. A few patients have superimposed autonomic insufficiency (87). Autopsy reports of neuronal loss in the dorsal root ganglia and autonomic ganglia with perivascular and perineuronal infiltration of T lymphocytes suggest a cell-mediated autoimmune process (87). Serum autoantibodies (distinct from anti-Hu antibodies) reacting with the cytoplasm of dorsal root ganglion neurons and Purkinje cells have been reported in several patients with nonparaneoplastic chronic sensory neuronopathy (127).

One described group of patients developed patchy, multifocal pain and loss of pinprick sensation in a non-length-dependent pattern, with sparing of large fiber sensation and no weakness or gait ataxia (64). None of the patients had anti-Hu antibodies or an identifiable neoplasm. The syndrome is believed, but not proven, to be a sensory ganglionopathy selectively affecting small nerve fibers.

Chronic sensory polyneuropathy may occur in patients with a serum IgM paraprotein reacting with GD1b and several other disialogangliosides (132; 60; 176; 09). Patients develop relapsing/remitting or steadily progressive numbness, paresthesias, areflexia, and sensory gait ataxia resembling paraneoplastic sensory neuronopathy. Some patients additionally have ophthalmoparesis and bulbar involvement, including respiratory insufficiency.

The spectrum of IgM paraproteinemia includes monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom macroglobulinemia, and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS), each of which may be associated with neuropathic symptoms mimicking a paraneoplastic sensory neuronopathy. Neuropathic features of POEMS often include calf pain, followed by slowly progressive dysesthesias in a length-dependent manner. Patients with evidence of IgM paraproteinemia and demyelinating neuropathy should be investigated for anti-MAG antibodies, though the anti-MAG syndrome tends to be more insidious than most paraneoplastic sensory neuronopathies, distal predominant, with a prominent tremor and vibratory loss (28).

Acute demyelinating polyneuropathy may rarely present with severe sensory loss and ataxia with minimal weakness (43; 95); the relationship of this disorder to Guillain-Barré syndrome is unclear.

A small subset of patients with CIDP has a slowly progressive, "clinically pure" sensory neuropathy with preserved strength (130). Abnormalities in motor nerve conduction studies and electrophysiological evidence of primary demyelination distinguish these patients from those with sensory neuronopathy. In some patients the inflammatory/demyelinating process preferentially affects large myelinated fibers in the posterior nerve roots, resulting in a chronic progressive sensory ataxia (157).

Patients with HIV infection frequently develop a distal, symmetric sensory neuropathy with prominent burning dysesthesias (59). The pathogenesis of this neuropathy is probably multifactorial and includes neurotoxic effects of antiretroviral drugs (135).

Among patients with a known cancer diagnosis, the differential diagnosis of sensory neuropathy also includes neurotoxicity of chemotherapy drugs (54; 80). Sensory neuropathy is the major dose-limiting toxicity of cisplatin when given for treatment of several carcinomas. Patients develop subacute, distal numbness and paresthesias, dysesthesias, areflexia, and sensory ataxia. Lhermitte symptom or muscle cramps are common. The neuropathy often worsens and spreads proximally even after cisplatin is discontinued. Carboplatin is much less likely than cisplatin to cause sensory neuropathy, but severe sensory neuropathy has been reported in patients who received high-dose carboplatin after prior cisplatin-based regimens. Oxaliplatin, when given in high cumulative doses, can cause a sensory neuropathy that resembles cisplatin neuropathy (113; 106). Although checkpoint inhibitors have been implicated in a number of paraneoplastic neurologic syndromes including limbic encephalitis, they have not yet been reported in the development of neuropathy (70). However, there have been cases of anti-Hu neuronopathies worsening after initiation of checkpoint inhibitors that block the action of program cell death-1 (PD-1) protein (142).

Paclitaxel or docetaxel can cause a pure or predominantly sensory neuropathy (112; 107). Numbness and dysesthesias usually begin distally in the legs but can be asymmetric or involve the hands or face early in the course. Motor involvement can occur in the most severely affected patients. The neuropathy is probably related to the cumulative drug dose, as well as to the single-dose intensity. Patients who receive paclitaxel or docetaxel plus cisplatin may be especially likely to develop sensory neuropathy.

A mainly sensory polyneuropathy can be the dose-limiting toxicity in patients with multiple myeloma treated with thalidomide or with the proteasome inhibitor bortezomib (138; 08; 49).

The microtubule-stabilizing chemotherapy agent ixabepilone can cause a predominantly sensory polyneuropathy (168).

No clinical or laboratory features absolutely distinguish paraneoplastic sensory neuronopathy from the other disorders mentioned above. If present, signs or symptoms of multifocal encephalomyelitis or abnormal cerebrospinal fluid (especially pleocytosis, oligoclonal bands, or elevated IgG index) should raise suspicion of a paraneoplastic disorder, as these features are rare among patients with non-paraneoplastic conditions.

The presence of any of the antineuronal antibodies listed in Table 1 is highly suggestive of the presence of an underlying tumor, especially small cell lung carcinoma. Antibody assays for diagnosing paraneoplastic disorders do, however, have some false positives and false negatives. Anti-Hu antibodies have not been found in patients with dorsal root ganglionitis or sensory neuropathy secondary to Sjögren syndrome, plasma cell dyscrasias, chemotherapy toxicity, or a variety of other etiologies (30). There is a single report of anti-Hu antibodies in a patient with systemic lupus erythematosus and polyradiculoneuropathy (15). In a small percentage of patients with sensory neuronopathy/multifocal encephalomyelitis and high-titer anti-Hu antibodies, an associated tumor is never identified, either at autopsy or after several years of clinical follow-up (40; 26). The neurologic presentation and course of these anti-Hu-positive, nonparaneoplastic patients cannot be distinguished from those of patients with paraneoplastic sensory neuronopathy/multifocal encephalomyelitis (115). Depending on the methodology used, low serum titers of anti-Hu antibodies are detected in 15% to 40% of patients with small cell lung carcinoma, but without clinically overt sensory neuronopathy or encephalomyelitis (38; 55; 71; 171; 123).

A minority of patients with small cell lung carcinoma and sensory neuronopathy or encephalomyeloneuritis either have no detectable antineuronal antibodies (51) or have "atypical" autoantibodies with a pattern of reactivity distinct from anti-Hu or other well-characterized antibodies.

Diagnostic workup

The characteristic electrophysiologic profile of paraneoplastic sensory neuronopathy includes severely reduced amplitude or complete absence of sensory nerve potentials, with normal or only slightly reduced sensory nerve conduction velocities if a response is able to be elicited (92; 31; 07; 133). The pattern of abnormalities does not typically manifest in a distal to proximal gradient, differentiating it from more common length-dependent neuropathies (111). Most patients do show at least some electrophysiologic abnormalities in motor nerve conduction studies, with or without symptoms of a mixed sensorimotor polyneuropathy (24; 111; 129); motor conduction studies are almost always less affected than sensory nerve studies. Needle EMG may show denervation in patients with a component of motor neuropathy or encephalomyelitis and anterior horn cell involvement. Sural nerve biopsy may show nonspecific axonal degeneration and a reduced population of myelinated fibers (07; 133).

Spine MR imaging in patients with paraneoplastic sensory neuronopathy may show nonspecific T2-weighted signal abnormalities in the posterior columns, reflecting degeneration of the central projections of dorsal root ganglia neurons (110; 111). Cerebral spinal fluid may demonstrate a mild pleocytosis (30 to 40 white blood cells per cubic millimeter), a slightly elevated protein level (50 to 100 mg/dL), or an elevated IgG level. The pleocytosis will typically only last for the first few weeks to months, though the elevated IgG will persist (92; 40; 148; 98). Of note, normal cerebral spinal fluid findings do not rule out the diagnosis (67). Many patients additionally have oligoclonal bands, an elevated cerebrospinal fluid IgG index, or both.

A reasonable starting workup for patients with sensory neuropathy or neuronopathy includes lumbar puncture, nerve conduction studies and EMG, and serum assays for antineuronal antibodies, immunofixation, Sjögren syndrome A and Sjögren syndrome B, and HIV-1 serology. Screening for serum paraneoplastic antineuronal antibodies is done by a number of commercial or research laboratories. It is generally agreed that the preferred method for detection of antineuronal antibodies is a combination of immunocytochemical and immunoblotting studies (122; 136). Paraneoplastic antibodies are more likely to be detected in patients with higher grade tumors and when tumor density is higher (29). It should be recalled that a few patients with paraneoplastic sensory neuronopathy do not have antineuronal antibodies, and that a few patients with antineuronal antibodies are never found to have a tumor. This work-up can often be conducted in the outpatient clinic.

In patients who are found to have anti-Hu or any of the antineuronal antibodies listed in Table 1, the search for a tumor should focus on small cell lung cancer, with chest CT, MR scanning, or PET (33; 164). The concurrent presence of anti-SOX2 antibodies in patients with a neurologic presentation and serum anti-Hu antibodies further raises suspicion for an association with small cell lung carcinoma (65). There are reported patients with sensory neuronopathy or encephalomyelitis and antineuronal antibodies in whom chest CT or MR scans were unrevealing, but total body fluorodeoxyglucose-PET scans demonstrated a lesion proven to be small cell lung carcinoma (85; 119). PET scanning does have some false positives and negatives in this setting. If initial cancer screening, which includes CT and fluorodeoxyglucose-PET scans, are negative, then repeat screening should be performed every 4 to 6 months for 2 years, although some authors recommend up to 4 years (164; 75). The yield of “blind” bronchoscopy without a definite radiographic pulmonary lesion is low. It is not uncommon for patients' initial evaluation for an occult lung tumor to be unrevealing; in these patients the workup should be repeated every several months and should include workup for other tumors, including lymphoma and carcinoma of the breast or prostate.

Management

Empirical antitumor treatment without a histologic cancer diagnosis in patients with suspected paraneoplastic sensory neuronopathy or encephalomyelitis is not recommended. When the tumor is definitely diagnosed, it should be treated with the appropriate surgical, chemotherapeutic, or radiation measures. Unfortunately, patients often attain a remission or apparent cure of the underlying tumor but remain neurologically disabled.

In conjunction with treatment of the tumor, a trial of immunosuppressive therapy should be considered for patients with paraneoplastic sensory neuronopathy or encephalomyelitis. Immunosuppressive therapy should also be offered to patients with a clinical diagnosis of sensory neuronopathy and positive serum anti-Hu antibodies but no detectable neoplasm. Corticosteroids or IVIg are the most commonly used immunotherapies for paraneoplastic disorders. Patients generally receive an initially high dose of intravenous or oral steroid (prednisone, methylprednisolone, dexamethasone) followed by a slow or rapid taper. No clear evidence indicates the optimal drug, dose, route of administration, or schedule of corticosteroids. IVIg may be tried alone or in combination with corticosteroids. There is probably no indication for repeated courses of IVIg if the first course is not clearly effective. If corticosteroids or IVIg are not beneficial, "second-line" therapy options could include plasma exchange, cyclophosphamide, or azathioprine. Rituximab may also be considered due to its depleting effects on B-cell antigen presenters necessary for T-cell activation (109). An open label trial of sirolimus on 17 patients with anti-Hu associated paraneoplastic syndromes demonstrated treatment response in seven patients (48). In an open phase II trial evaluating the use of natalizumab in 15 patients with Anti-Hu associated sensory neuronopathy, objective improvement was reported in only 10% of patients although stability was seen in 60% of patients (13). These results may be driven, in part, by the short follow-up time of the trial. Symptomatic management of the patient’s pain may include the use of medication such as gabapentin, pregabalin, duloxetine, and venlafaxine (83). Major neurologic improvement is unlikely, but successful tumor treatment and early immunotherapy may increase the likelihood of at least some neurologic improvement (81).

There is theoretical concern that if the paraneoplastic disorder arises from an immune response directed against the tumor, attempts to treat the neurologic disorder with immunosuppression may adversely affect the evolution of the tumor. At this time, there is no definite evidence that patients given immunosuppressive treatment have a worse tumor outcome than those who are not (100).

Outcomes

Patients with paraneoplastic sensory neuronopathy rarely show significant neurologic improvement despite successful tumor treatment or a variety of immunosuppressive therapies, including prednisone, high-dose methylprednisolone, cyclophosphamide, IVIg, or plasmapheresis, whether alone or in combination (31; 40; 74; 167; 100; 101; 73; 154). It is difficult to interpret reports of "stabilization" of paraneoplastic sensory neuronopathy or encephalomyelitis with immunosuppression because the disease stabilizes spontaneously in most patients. Patients with a relatively short history of neurologic symptoms and who have successful treatment of the associated neoplasm may have a slightly better likelihood of neurologic stabilization or improvement (73; 26). Otherwise, nothing is distinctive about the clinical presentation of the few patients with paraneoplastic sensory neuronopathy and antineuronal antibodies who improve after immunosuppression, tumor treatment, or both (167; 128; 165; 35). Sirolimus suppresses cytokine-mediated T-lymphocyte proliferation and may, therefore, block cell-mediated neuronal injury. A small prospective study of sirolimus for patients with anti-Hu-associated paraneoplastic disorders, including sensory neuronopathy, did not show clearly better neurologic outcomes than those reported with other immunotherapies (48).

There are several potential explanations for the generally poor results of immunosuppressive therapy. It is possible that plasmapheresis or systemic immunosuppressive drugs do not adequately treat an autoimmune response "sequestered" within the CNS. Unfortunately, it is also more likely that at the time of diagnosis, many patients with paraneoplastic sensory neuronopathy or encephalomyelitis have already suffered irreversible neuronal damage or loss. This is supported by the typical monophasic clinical course in which patients deteriorate subacutely and then level off at a level of severe disability.

In contrast to the patients with paraneoplastic sensory neuronopathy and small cell lung carcinoma, several patients with Hodgkin disease have shown significant neurologic improvement following successful chemotherapy (150; 22; 137). There is evidence that the sensory neuropathy associated with Hodgkin disease is a demyelinating polyneuropathy rather than a dorsal root ganglionitis.

References

01: Altermatt HJ, Rodriguez M, Scheithauer BW, Lennon VA. Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest 1991;65:412-20. PMID 1921331
02: Amato AA, Russell JA. Toxic neuropathies. Neuromuscular disorders. 2nd edition. Boston, MA: McGraw-Hill Education Medical, 2016.
03: Amato AA, Ropper AH. Sensory ganglionopathy. N Engl J Med 2020;383(17):1657-62. PMID 33085862
04: Antoine JC. Inflammatory sensory neuronopathies. Rev Neurol (Paris) 2024. [Epub ahead of print] PMID 38472032
05: Antoine JC, Camdessanché JP. Paraneoplastic Neuropathies. Curr Opin Neurol 2017;30(5):513-20. PMID 28682959
06: Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001;49:214-21. PMID 11220741
07: Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999;67:7-14. PMID 10369814
08: Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593-9. PMID 18574024
09: Attarian S, Boucraut J, Hubert AM, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 2010;81(1):61-4. PMID 19726417
10: Ayrignac X, Castelnovo G, Landrault E, et al. [Ma2 antibody and multiple mononeuropathies]. Rev Neurol (Paris) 2008;164(6-7):608-11. PMID 18565361
11: Baird AD, Cornford PA, Helliwell T, Woolfenden KA. Small cell prostate cancer with anti-Hu positive peripheral neuropathy. J Urol 2002;168(1):192. PMID 12050524
12: Basal E, Zalewski N, Kryzer TJ, et al. Paraneoplastic neuronal intermediate filament autoimmunity. Neurology 2018;91(18):e1677-89. PMID 30282771
13: Bastiaansen AE, de Jongste AH, de Bruijn MA, et al. Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neurooncol Adv 2021;3(1):vdab145. PMID 34693289
14: Bechich S, Graus F, Arboix A, Isidro A, Marti M, Rosell F. Anti-Hu-associated paraneoplastic sensory neuropathy and breast cancer. J Neurol 2000;247:552-3. PMID 10993499
15: Benyahia B, Amoura Z, Rousseau A, et al. Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases. J Neuro Oncol 2003;62:349-51. PMID 12777089
16: Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurologic syndromes with anti-Hu antibodies. Ann Neurol 1999;45:162-7. PMID 9989617
17: Bernal F, Graus F, Pifarre A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 2002;103(5):509-15. PMID 11935268
18: Bi WL, Bannykh SI, Martel M, Baehring JM. Paraneoplastic subacute sensory neuronopathy secondary to a malignant mixed mullerian tumor. Obstet Gynecol 2006;107(2 Pt 2):504-6. PMID 16449165
19: Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135:1622-38. PMID 22539258
20: Bolognani F, Contente T, Perrone NI. Novel recognition motifs and biological functions of the RNS-binding protein HuD revealed by genome-wide identification of its targets. Nucl Acids Res 2010;38:117-30. PMID 19846595
21: Bronicki LM, Jasmin BJ. Emerging complexity of the HuD/ELAV gene; implications for neuronal development, function, and dysfunction. RNA 2013;19(8):1019-37. PMID 23861535
22: Brunet P, Schadeck B, Moriceau M. Subacute sensory neuropathy with remission: an association with lymphoma. J Neurol Neurosurg Psychiatry 1983;46:99-100. PMID 6842213
23: Byrne T, Mason WP, Posner JB, Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997;62:276-8. PMID 9069485
24: Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002;125(Pt 1):166-75. PMID 11834602
25: Camdessanche JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009;132:1723-33. PMID 19506068
26: Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neuro Neurosurg Psychiatry 2004;75(10):1411-5. PMID 15377687
27: Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998;4(11):2819-24. PMID 9829748
28: Carroll AS, Lunn MPT. Paraproteinaemic neuropathy: MGUS and beyond. Pract Neurol 2021;21(6):492-503. PMID 34282034
29: Ceyhun S, Hülya T, Erdem T, Meryem GG, Fügen VA. Determination of Paraneoplastic neuropathy in newly diagnosed breast tumor patients. eNeurologicalSci 2020;21:100265. PMID 32984562
30: Chalk CH, Lennon VA, Stevens JC, Windebank AJ. Seronegativity for type 1 antineuronal nuclear antibodies in subacute sensory neuronopathy patients with cancer. Neurology 1993;43:2209-11. PMID 8232930
31: Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992;19:346-51. PMID 1393844
32: Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50(3):301-11. PMID 11558786
33: Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Roentgenol 1998;170(6):1513-7. PMID 9609164
34: Coppens T, van den Bergh P, Duprez TJ, Jeanjean A, De Ridder F, Sindic CJ. Paraneoplastic rhombencephalitis and brachial plexopathy in two cases of amphiphysin autoimmunity. Eur Neurol 2006;55(2):80-3. PMID 16567945
35: Coret F, Bosca I, Fratalia L, Perez-Griera J, Pascual A, Casanova B. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol 2009;93(3):421-3. PMID 19139820
36: Croft PB, Henson RA, Urich H, Wilkinson PC. Sensory neuropathy with bronchial carcinoma: a study of four cases showing serological abnormalities. Brain 1965;88:501-14. PMID 4284066
37: Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986;19:545-54. PMID 3014995
38: Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol 1990;27(5):544-52. PMID 2163235
39: Dalmau J, Graus F, Cheung NK, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995;75(1):99-109. PMID 7804984
40: Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992;71(2):59-72. PMID 1312211
41: Daniel SE, Love S, Scaravilli F, Harding AE. Encephalomyeloneuropathy in the absence of a detectable neoplasm. Acta Neuropathol 1985;66:311-7. PMID 4013679
42: Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993;341:21-2. PMID 8093269
43: Dawson DM, Samuels MA, Morris J. Sensory form of acute polyneuritis. Neurology 1988;38:1728-31. PMID 3185907
44: de Beukelaar JW, Verjans GM, van Norden Y, et al. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother 2007;56:1501-6. PMID 17597332
45: de Graaf M, de Beukelaar J, Bergsma J, et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol 2008;195(1-2):164-70. PMID 18358542
46: de Jongste AH, de Graaf MT, Martinuzzi E, et al. Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies. Neuro Oncol 2012;14(7):841-8. PMID 22591661
47: de Jongste AH, de Graaf MT, van den Broek PD, Kraan J, Smitt PA, Gratama JW. Elevated numbers of regulatory T cells, central memory T cells and class-switched B cells in CSF of patients with anti-Hu antibody associated paraneoplastic neurological syndromes. J Neuroimmunol 2013;258(1-2):85-90. PMID 23566401
48: de Jongste AH, van Gelder T, Bromberg JE, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndrome. Neuro Oncol 2015;17(1):145-50. PMID 24994790
49: Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95. PMID 20932799
50: Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948;11:73-87. PMID 18861108
51: Drlicek M, Bodenteich A, Setinek U, Tucek G, Urbanits S, Grisold W. T cell-mediated paraneoplastic ganglionitis--an autopsy case. Acta Neuropathol (Berl) 2000;99(5):599-602. PMID 10805108
52: Dropcho EJ. Antiamphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996;39:659-67. PMID 8619552
53: Dropcho EJ. Remote neurologic manifestations of cancer. Neurol Clin 2002;20(1):85-122. PMID 11754303
54: Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol 2010;30(3):273-86. PMID 20577934
55: Dropcho EJ, King PH. Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies. Ann Neurol 1994;36:200-5. PMID 8053656
56: Dubey D, Honorat JA, Shelly S, et al. Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm 2020;7(4):e771. PMID 32461352
57: Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 2018;90(2):e103-10. PMID 29222126
58: Eggers C, Hagel C, Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. J Neurol Sci 1998;155:178-81. PMID 9562263
59: Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of HIV-associated sensory neuronopathy in the era of combination antiretroviral therapy. Arch Neurol 2010;67:552-8. PMID 20457954
60: Eurelings M, Ang CW, Notermans NC, Van Doom PA, Jacobs BC, Van den Berg LH. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001;57(10):1909-12. PMID 11723289
61: Feldheim J, Deuschl C, Glas M, Kleinschnitz C, Hagenacker T. Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies. Neurol Res Pract 2021;3(1):30. PMID 34030742
62: Geng G, Yu X, Jiang J, Yu X. Aetiology and pathogenesis of paraneoplastic autoimmune disorders. Autoimmun Rev 2020;19(1):102422. PMID 31733369
63: Gill S, Murray N, Dalmau J, Thiessen B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 2003;30:269-71. PMID 12945955
64: Gorson KC, Herrmann DN, Thiagarajan R, et al. Non-length dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatr 2008;79:163-9. PMID 17911181
65: Gozzard P, Chapman C, Vincent A, Lang B, Maddison P. Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study. PLoS ONE 2015a;10(11):e0143558. PMID 26606748
66: Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology 2015b;85(3):235-9. PMID 26109714
67: Grativvol RS, Cavalcante WCP, Castro LHM, Nitrini R, Simabukuro MM. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr Oncol Rep 2018;20(11):92. PMID 30415318
68: Graus F, Bonaventura I, Uchuya M, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994;44:2258-61. PMID 7991109
69: Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985;35:538-43. PMID 2984600
70: Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019;16(9):535-48. PMID 30867573
71: Graus F, Dalmau J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-72. PMID 9256130
72: Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75(8):1135-40. PMID 15258215
73: Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(Pt 6):1138-48. PMID 11353730
74: Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992;42:536-40. PMID 1312683
75: Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmun Neuroinflam 2021;8(4):e1014. PMID 34006622
76: Gravier-Dumonceau A, Ameli R, Rogemond V, et al. Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology 2022;98(6):e653-68. PMID 34799461
77: Greenlee JE, Parks TN, Jaeckle KA. Type IIa ("anti-Hu") antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology 1993;43:2049-54. PMID 8413965
78: Greenlee JE, Steffens JD, Clawson SA, Hill K, Dalmau J. Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 2002;52(1):111-5. PMID 12112058
79: Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol 1990;27:304-15. PMID 2327738
80: Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012;14 Suppl 4:iv45-54. PMID 23095830
81: Grisold W, Grisold A, Löscher WN. Neuromuscular complications in cancer. J Neurol Sci 2016;367:184-202. PMID 27423586
82: Gupta N, Yuil-Valdes A, Piccione EA. Anti-Hu (ANNA-1) associated paraneoplastic sensory neuronopathy in a large cell neuroendocrine carcinoma of the lung. Can J Neurol Sci 2023;50(2):308-9. PMID 35272731
83: Gwathmey KG. Sensory neuronopathies. Muscle Nerve 2016;53(1):8-19. PMID 26467754
84: Gwathmey KG. Sensory neuronopathies. Continuum (Minneap Minn) 2017;23(5):1411-36. PMID 28968369
85: Hadjivassiliou M, Alder SJ, Van Beek EJ, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009;119(3):186-93. PMID 18855873
86: Hadjivassiliou M, Rao DG, Wharton SB, et al. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010;75:1003-8. PMID 20837968
87: Hainfellner HA, Kristoferitsch W, Lassmann H, et al. T cell-mediated ganglionitis associated with acute sensory neuronopathy. Ann Neurol 1996;39:543-7. PMID 8619534
88: Henson RA, Hoffman HL, Urich H. Encephalomyelitis with carcinoma. Brain 1965;88:449-64. PMID 5890519
89: Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008;65(20):3168-81. PMID 18581050
90: Hormigo A, Lieberman F. Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol 1994;55:205-12. PMID 7829670
91: Horoupian DS, Kim Y. Encephalomyeloneuropathy with ganglionitis of the myenteric plexuses in the absence of cancer. Ann Neurol 1982;11:628-31. PMID 7114813
92: Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 1977;2:7-19. PMID 197875
93: Ichimura M, Yamamoto M, Kobayashi Y, et al. Tissue distribution of pathological lesions and Hu antigen expression in paraneoplastic sensory neuronopathy. Acta Neuropathol 1998;95:641-8. PMID 9650757
94: Inuzuka T, Hayashi Y, Kimura A. Paraneoplastic neurological syndrome. Neuroimmunol Dis 2016;8:245-57.
95: Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain-Barre syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82(3):294-9. PMID 21252265
96: Iwahashi T, Inoue A, Koh CS, Yanagisawa N. A study on a new antineural antibody in a case of paraneoplastic sensory neuropathy associated with breast carcinoma. J Neurol Neurosurg Psychiatry 1997;63:516-9. PMID 9343135
97: Jarius S, Ringelstein M, Haas J, et al. Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. J Neuroinflammation 2016;3(1)278. PMID 27776522
98: Jitprapaikulsan J, Paul P, Thakolwiboon S, Mittal SO, Pittock SJ, Dubey D. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Pract 2021;8(4):362-74. PMID 34277016
99: Johnson PC, Rolak LA, Hamilton RH, Laguna JF. Paraneoplastic vasculitis of nerve: a remote effect of cancer. Ann Neurol 1979;5:437-44. PMID 223493
100: Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999;53:1719-23. PMID 10563618
101: Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000;68:479-82. PMID 10727484
102: King PH, Dropcho EJ. Expression of Hel-N1 and Hel-N2 in small cell lung carcinoma. Ann Neurol 1996;39:679-81. PMID 8619556
103: King PH, Levine TD, Fremeau RT, Keene JD. Mammalian homologs of Drosophila ELAV localized to a neuronal subset can bind in vitro to the 3' UTR of mRNA encoding the Id transcriptional repressor. J Neurosci 1994;14:1943-52. PMID 8158249
104: Koike H, Atsuta N, Adachi H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010;133(10):2881-96. Brain 2010;133(10):2881-96. PMID 20736188
105: Koike H, Sobue G. 2013. Paraneoplastic neuropathy. Handb Clin Neurol 2013;115:713-26. PMID 23931811
106: Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60. PMID 15880395
107: Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. Clin Cancer Res 2013;19(17):4570-7. PMID 23817688
108: Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 2004;30(3):255-68. PMID 15318336
109: Lancaster E. Paraneoplastic disorders. CONTINUUM (Minneap Minn) 2017;23(6):1653-79. PMID 29200116
110: Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 2000;47:104-9. PMID 10632108
111: Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. Eur Neurol 2003;50(3):146-52. PMID 14530620
112: Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42. PMID 16575015
113: Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29(3):387-92. PMID 14981738
114: Li J, Lin W. Various clinical features of patients with anti-hu associated paraneoplastic neurological syndromes: an observational study. Medicine (Baltimore) 2018;97(18):e0649. PMID 29718880
115: Llado A, Carpentier AF, Honnorat J, et al. Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 2006;77(8):996-7. PMID 25304728
116: Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type I antineuronal nuclear autoantibodies. Neurology 1998;50:652-7. PMID 9521251
117: Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995;38:102-10. PMID 7541976
118: Mathis S, Duval F, Soulages A, Solé G, Le Masson G. The ataxic neuropathies. J Neurol 2021;268(10):3675-89. PMID 32556571
119: McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010;67(3):322-9. PMID 20065123
120: McNamara P, Costelloe L, Langan Y, Redmond J. Anti-Yo postitive dorsal root ganglionopathy. J Neurol 2011;258:519-20. PMID 20931213
121: Molinuevo JL, Graus F, Serrano C, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998;44:976-80. PMID 9851446
122: Moll JW, Antoine JC, Brashear HR, et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies. Neurology 1995;45:1937-41. PMID 7478000
123: Monstad SE, Drivsholm L, Storstein A, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004;22(5):795-800. PMID 14990634
124: Mori K, Lijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 2005;128(Pt 11):2518-34. PMID 16049042
125: Muller NG, Prass K, Zschenderlien R. Anti-Hu antibodies, sensory neuropathy, and Holmes-Adie syndrome in a patient with seminoma. Neurology 2005;64(1):164-5. PMID 15642929
126: Mutoh T, Tachi M, Yano S, Mihara T, Yamamoto H. Impairment of Trk-neurotrophin receptor by the serum of a patient with subacute sensory neuropathy. Acta Neurol 2005;62(10):1612-5. PMID 16216947
127: Nemni R, Camerlingo M, Fazio R, et al. Serum antibodies to Purkinje cells and dorsal root ganglia neurons in sensory neuronopathy without malignancy. Ann Neurol 1993b;34:848-54. PMID 8250535
128: Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997;20(12):1576-82. PMID 9390671
129: Oh SJ, Gurtekin Y, Dropcho EJ, et al. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005;116(1):28-34. PMID 15589180
130: Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677-80. PMID 1326601
131: Ohnishi A, Ogawa M. Preferential loss of large lumbar primary sensory neurons in carcinomatous sensory neuropathy. Ann Neurol 1986;20:102-4. PMID 3017184
132: Oka N, Kusaka H, Kusunoki S, et al. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 1996;19:528-30. PMID 8622736
133: Oki Y, Koike H, Iijima M, et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology 2007;69:564-72. PMID 17679675
134: Panegyres PK, Reading MC, Esiri MM. The inflammatory reaction of paraneoplastic ganglionitis and encephalitis: an immunohistochemical study. J Neurol 1993;240:93-7. PMID 8382274
135: Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59(5):816-24. PMID 16634006
136: Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56(5):715-9. PMID 15468074
137: Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin's disease. J Neurol Sci 1994;121:155-8. PMID 8158207
138: Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007;69:573-81. PMID 17679676
139: Plonquet A, Garcia-Pons F, Fernandez E, et al. Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 2003;142(1-2):93-100. PMID 14512168
140: Plonquet A, Gherardi RK, Creange A, et al. Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 2002;122(1-2):100-5. PMID 11777548
141: Poepel A, Jarius S, Heukamp LC, et al. Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome. J Neurol Sci 2007;263:145-8. PMID 17706677
142: Raibagkar P, Ho D, Gunturu KS, Srinivasan J. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and review of literature. J Neuroimmunol 2020;341:577184. PMID 32058173
143: Raspotnig M, Vedeler C, Storstein A. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies. J Neurol Sci 2015;348(1-2):41-5. PMID 25467140
144: Rauer S, Czygan M, Kaiser R. Quantification of circulating anti-Hu antibody in serial samples from patients with paraneoplastic neurological syndromes: possible correlation of antibody concentration and course of neurological symptoms. J Neurol 2002;249:285-9. PMID 11993527
145: Rauer S, Kaiser R. Demonstration of anti-HuD specific oligoclonal bands in the CSF from patients with paraneoplastic neurological syndromes. J Neuroimmunol 2000;111:241-4. PMID 11063845
146: Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry 2004;75 Suppl 2(Suppl 2):ii43-50. PMID 15146039
147: Rojas-Marcos I, Rousseau A, Keime-Guibert F, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine 2003;82:216-23. PMID 12792307
148: Rosenfeld MR, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin 2018;36(3):675-85. PMID 30072076
149: Rousseau A, Benyahia B, Dalmau J, et al. T-cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005;71(3):231-6. PMID 15735910
150: Sagar HJ, Read DJ. Subacute sensory neuropathy with remission: an association with lymphoma. J Neurol Neurosurg Psychiatry 1982;45:83-5. PMID 6278098
151: Sakai K, Gofuku M, Kitagawa Y, et al. A hippocampal protein associated with paraneoplastic neurologic syndrome and small cell lung carcinoma. Biochem Biophys Res Commun 1994;199:1200-8. PMID 7511893
152: Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med 1983;309:445-8. PMID 6308447
153: Sekido Y, Bader SA, Carbone DP, Johnson BE, Minna JD. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res 1994;54:4988-92. PMID 8069866
154: Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002;249:745-53. PMID 12111309
155: Sillevis Smitt P, Manley G, Dalmau J, Posner J. The HuD paraneoplastic protein shares immunogenic regions between PEM/PSN patients and several strains and species of experimental animals. J Neuroimmunol 1996;71(1-2):199-206. PMID 8982120
156: Sillevis Smitt P, Manley G, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995;45:1873-8. PMID 7477985
157: Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possible treatable sensory ataxia. Neurology 2004;63(9):1662-9. PMID 15534252
158: Szabo A, Dalmau J, Manley G, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 1991;67(2):325-33. PMID 1655278
159: Taieb G, Renard D, Deverdal M, Honnorat J, Labauge P, Castelnovo G. Pure monomelic sensory neuronopathy associated with anti-yo antibodies. Muscle Nerve 2012;45(2):297-8. PMID 22246892
160: Tanaka K, Ding X, Tanaka M. Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary cultured neurons. J Neurol Sci 2004;217(1):25-30. PMID 14675605
161: Tanaka M, Maruyama Y, Sugie M, et al. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 2002;201:9-12. PMID 12163187
162: Tanaka K, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cytotoxic T lymphocyte-mediated cell death in paraneoplastic sensory neuronopathy with anti-Hu antibody. J Neurol Sci 1999;163:159-62. PMID 10371077
163: Theuriet J, Cluse F, Gravier-Dumonceau A, et al. Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease. J Neurol 2023;270(11):5545-60. PMID 37540278
164: Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19-e3. PMID 20880069
165: Toepfer M, Schroeder M, Unger JW, Lochmuller H, Pongratz D, Muller-Felber W. Neuromyotonia, myoclonic, sensory neuropathy and cerebellar symptoms in a patient with antibodies to neuronal nucleoproteins (anti-Hu antibodies). Clin Neurol Neurosurg 1999;101:207-9. PMID 10536910
166: Tschernatsch M, Singh P, Gross O, et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Neuroimmunol 2010;226(1-2):177-80. PMID 20701982
167: Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 1996;60:388-92. PMID 8774401
168: Vahdat LT, Thomas ES, Roche HH, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 2012;20(11):2661-8. PMID 22382588
169: Vega F, Graus F, Chen QM, Poisson M, Schuller E, Delattre JY. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlations. Neurology 1994;44:2145-7. PMID 7969974
170: Vernino S, Eggenberger ER, Rogers LR, Lennon VA. Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. Neurology 2002;59(6):929-32. PMID 12297583
171: Verschuuren JJ, Perquin M, ten Velde G, De Baets M, Vriesman P, Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry 1999;67(3):353-7. PMID 10449558
172: Verschuuren JJ, Twijnstra A, De Baets M, et al. Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma. Neurology 1994;44(8):1551-2. PMID 8058170
173: Villagrán-García M, Muñiz-Castrillo S, Ciano-Petersen NL, et al. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol 2023;270(1):283-99. PMID 36397418
174: Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998;51:1146-50. PMID 9781545
175: Wanschitz J, Hainfellner JA, Kristoferitsch W, Drlicek M, Budka H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 1997;49:1156-9. PMID 9339709
176: Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;124(Pt 10):1968-77. PMID 11571215
177: Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy. Neurology 1990;40:584-91. PMID 2157173
178: Younger DS, Dalmau J, Inghirami G, Sherman WH, Hays AP. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology 1994;44:181-3. PMID 8290066
179: Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-54. PMID 11220734
180: Zekeridou A, Majed M, Heliopoulos I, Lennon VA. Paraneoplastic autoimmunity and small-cell lung cancer: neurological and serological accompaniments. Thorac Cancer 2019;10(4):1001-4. PMID 30810271
181: Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic neuropathies: what's new since the 2004 recommended diagnostic criteria. Front Neurol 2021;12:706169. PMID 34659082

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Arjun Seth MD

Dr. Seth of Northwestern University Feinberg School of Medicine received consultant fees from Argenx, Takeda, and UCB Pharma.
See Profile
Glenn R Harris MD

Dr. Harris of Northwestern University, Feinberg School of Medicine, has no relevant financial relationships to disclose.
See Profile

Editor

Rimas V Lukas MD

Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from Novartis and Novocure for speaking engagements, honorariums from Cardinal Health, Novocure, and Merck for advisory board membership, and research support from BMS as principal investigator.
See Profile

Former Authors

Edward J Dropcho MD
Jinny O Tavee MD
Hamza Malek MD

Patient Profile

Age range of presentation: 13 to 65+ years
Sex preponderance: female>male, >1:1
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Paraneoplastic sensory neuronopathy

Associated Disorders

Cerebellar ataxia
Dorsal root ganglionitis
Paraneoplastic cerebellar degeneration
Paraneoplastic encephalomyeloneuritis
Paraneoplastic limbic encephalitis
- Small cell lung carcinoma
- Subacute sensory neuronopathy

Differential Diagnosis

multifocal encephalomyeloneuritis
prominent sensory neuronopathy
Sjögren syndrome
gluten sensitivity
predominant loss of proprioception
- predominant loss of vibratory sense
- pseudoathetosis
- areflexia
- sensory gait ataxia
- Lhermitte symptom
- symmetric, pure sensory neuropathy due to pyridoxine abuse
- sensory loss and ataxia with acute demyelinating polyneuropathy
- chronic inflammatory demyelinating polyneuropathy
- distal, symmetric sensory neuropathy with HIV infection
- chronic sensory neuropathy with primary biliary cirrhosis
- neurotoxicity of chemotherapy drugs cisplatin and taxol

Also Relevant

Guillain-Barre syndrome in children
Lambert-Eaton myasthenic syndrome
Paraneoplastic cerebellar degeneration
Paraneoplastic limbic encephalitis
Paraneoplastic syndromes
- Sjogren syndrome: neurologic complications
- Small fiber neuropathies

Clinical Categories

Patient Handouts

Paraneoplastic syndromes

Paraneoplastic sensory neuronopathy …

Paraneoplastic sensory neuronopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Antineuronal Antibodies in Paraneoplastic Sensory Neuronopathy and Sensorimotor Polyneuropathy

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Familial dysautonomia

Tumors of the skull base

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Multiple sclerosis: treatment of its symptoms

Disulfiram neuropathy

Paraneoplastic sensory neuronopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Antineuronal Antibodies in Paraneoplastic Sensory Neuronopathy and Sensorimotor Polyneuropathy

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Familial dysautonomia

Tumors of the skull base

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Multiple sclerosis: treatment of its symptoms

Disulfiram neuropathy

This is an article preview.
Start a Free Account
to access the full version.